Nautilus Biotechnology, Inc. (NAUT) Guidance & Earnings Results
On 2026-02-26 Nautilus Biotechnology, Inc. issued guidance: "FY2026 operating expenses expected to increase by approximately 15–20% year over year compared to 2025; no material revenue expected from Early Access Program engagements in 2026; cash runway through 2027 based on…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NAUTNautilus Biotechnology, Inc.Follow NAUT — free
—
Price chart with a free account
- Market cap
- 412.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 26 Feb 26 | — | FY2026 operating expenses expected to increase by approximately 15–20% year over year compared to 2025; no material revenue expected from Early Access Program engagements in 2026; cash runway through 2027 based on $156.1M cash. |
Nautilus Biotechnology, Inc. — questions
- What guidance did Nautilus Biotechnology, Inc. give?
- On 2026-02-26: "FY2026 operating expenses expected to increase by approximately 15–20% year over year compared to 2025; no material revenue expected from Early Access Program engagements in 2026; cash runway through 2027 based on $156.1M cash."
- When does Nautilus Biotechnology, Inc. report earnings?
- Nautilus Biotechnology, Inc.'s next earnings report is expected on 2026-10-27.
Every figure on this page comes from Nautilus Biotechnology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.